https://medicaldialogues.in/news/industry/pharma/usfda-nod-to-bristol-myers-squibb-2seventy-bio-abecma-for-triple-class-exposed-relapsed-or-refractory-multiple-myeloma-after-2-prior-lines-of-therapy-126875